Bristol-Myers Squibb to sell its global diabetes business

6th January 2014

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca.

Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.

Read more at source article

Leave a Reply

Your email address will not be published.

31 + = 33

« back to posts